University of Missouri-Columbia College of Veterinary Medicines


Applying
| Calendars | Contact | News & Events

Prospective StudentsCurrent StudentsAlumni and FriendsFaculty and StaffVeterinarians

About the College

Departments

Teaching & Research

Giving to Vet Med

Teaching Hospital

Veterinary Medical Diagnostic Laboratory (VMDL)

CVM Employment

Zalk Veterinary Medical Library

CVM Course Materials

MyZou

Home

 

News and Events

Molecular Therapy for Spinal Muscular
Atrophy Closer to Clinical Use
-MU researcher improves efficiency of trans-splicing therapy

Spinal muscular atrophy, a neurodegenerative disorder that causes the weakening of muscles, is the leading cause of infant death and occurs in 1 in 6,000 live births. While trans-splicing (a form of molecular therapy) has had impressive results as a treatment for spinal muscular atrophy in cell-based models of disease, scientists have been unable to translate the therapy to the human body. A University of Missouri researcher has developed a strategy that will enhance trans-splicing activity and bring it closer to being used in the clinical setting.

Spinal muscular atrophy is caused by the loss of survival motor neuron-1(SMN1). In humans, a nearly identical copy gene is present called SMN2. Because of a single molecular difference, SMN2 alone cannot compensate for the loss of SMN1, but it can be used as a primary target for therapeutics, including trans-splicing. Trans-splicing therapy relies on splicing, or uniting, of mutant RNA and therapeutic RNA in order to correct RNA sequence.

To improve efficiency, the researchers developed a trans-splicing system that uses a strand of RNA that can bind to a gene and inactivate it. Turning the gene “off” reduces competition at splice sites and improves the likelihood of achieving the desired results.

“The key to introducing trans-splicing in clinical settings is developing efficient trans-splicing systems,” said Chris Lorson, investigator in the Christopher S. Bond Life Sciences Center; associate professor of veterinary pathobiology in the MU College Veterinary Medicine; and scientific director for Fight SMA, a private spinal muscular atrophy research foundation in Richmond, Va. “We have found that reducing the competition between the splice sites enhances the efficiency of trans-splicing. This strategy provides insight into the trans-splicing mechanism and significantly improves trans-splicing activity in a mouse model of spinal muscular atrophy. ”

The study, “Development of a Single Vector System that Enchances Trans-splicing of SMN2 Transcripts,” was published in PLoS ONE and was co-authored by Lorson; MU researchers Tristan H. Coady, Travis D. Baughan and Monir Shababi; and Genzyme Corporation neuroscience researcher Marco A. Passini.

 

Story courtesy of the University of Missouri News Bureau

Return to News and Events home

College of Veterinary Medicine
W-203 Veterinary Medicine Building
Columbia, MO 65211
Phone: (573) 882-3554
E-mail: cvmwebmaster@missouri.edu
Like us on Facebook
©2005 Curators of the University of Missouri
DMCA and other copyright information.
an equal opportunity/ADA institution

Last Update: February 24, 2012